JO3122B1 - مشتقات إسترا-5،3،1(10)، 16- تترايين-3- كربوكساميد، عمليات لتحضيرها، مستحضرات دوائية تشتمل عليها واستخدامها لتحضير أدوية - Google Patents

مشتقات إسترا-5،3،1(10)، 16- تترايين-3- كربوكساميد، عمليات لتحضيرها، مستحضرات دوائية تشتمل عليها واستخدامها لتحضير أدوية

Info

Publication number
JO3122B1
JO3122B1 JOP/2012/0285A JOP20120285A JO3122B1 JO 3122 B1 JO3122 B1 JO 3122B1 JO P20120285 A JOP20120285 A JO P20120285A JO 3122 B1 JO3122 B1 JO 3122B1
Authority
JO
Jordan
Prior art keywords
preparations
preparation
tetraine
astra
carboxamide
Prior art date
Application number
JOP/2012/0285A
Other languages
English (en)
Inventor
Marquardt Tobias
Andrea Rotgeri Dr
Ingo Hartung Dr
Oliver Martin Fischer Dr
Isabella Gashaw Dr
Matthias Busemann Dr
Naomi Barak Dr
Ulrich Bothe Dr
Original Assignee
Bayer Ip Gmbh
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46963705&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3122(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ip Gmbh, Bayer Pharma AG filed Critical Bayer Ip Gmbh
Application granted granted Critical
Publication of JO3122B1 publication Critical patent/JO3122B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

يتعلق الاختراع بمثبطات AKR1C3 وبعمليات (processes) لتحضيرها، باستخدامها لمعالجة و/أو الوقاية من أمراض وأيضا باستخدامها لتحضير أدوية (medicaments) لمعالجة و/أو الوقاية من أمراض، بالتحديد الاضطرابات النزيفية والانتباذ البطاني الرحمي.
JOP/2012/0285A 2011-09-29 2012-09-27 مشتقات إسترا-5،3،1(10)، 16- تترايين-3- كربوكساميد، عمليات لتحضيرها، مستحضرات دوائية تشتمل عليها واستخدامها لتحضير أدوية JO3122B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102011083725A DE102011083725A1 (de) 2011-09-29 2011-09-29 Estra-1,3,5(10),16-tetraen-3-carboxamid-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln

Publications (1)

Publication Number Publication Date
JO3122B1 true JO3122B1 (ar) 2017-09-20

Family

ID=46963705

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2012/0285A JO3122B1 (ar) 2011-09-29 2012-09-27 مشتقات إسترا-5،3،1(10)، 16- تترايين-3- كربوكساميد، عمليات لتحضيرها، مستحضرات دوائية تشتمل عليها واستخدامها لتحضير أدوية

Country Status (42)

Country Link
US (1) US9487554B2 (ar)
EP (1) EP2760878B1 (ar)
JP (1) JP5791810B2 (ar)
KR (1) KR20140069013A (ar)
CN (1) CN103827133B (ar)
AP (1) AP2014007598A0 (ar)
AR (1) AR088180A1 (ar)
AU (1) AU2012314627B2 (ar)
BR (1) BR112014007223A2 (ar)
CA (1) CA2850047C (ar)
CL (1) CL2014000775A1 (ar)
CO (1) CO6920294A2 (ar)
CR (1) CR20140144A (ar)
CU (1) CU20140037A7 (ar)
CY (1) CY1117123T1 (ar)
DE (1) DE102011083725A1 (ar)
DK (1) DK2760878T3 (ar)
DO (1) DOP2014000059A (ar)
EA (1) EA025518B9 (ar)
EC (1) ECSP14013275A (ar)
ES (1) ES2560257T3 (ar)
GT (1) GT201400059A (ar)
HR (1) HRP20160050T1 (ar)
HU (1) HUE026645T2 (ar)
IL (1) IL231755A (ar)
JO (1) JO3122B1 (ar)
MA (1) MA35455B1 (ar)
MX (1) MX2014003823A (ar)
MY (1) MY175804A (ar)
PE (1) PE20141554A1 (ar)
PH (1) PH12014500674A1 (ar)
PL (1) PL2760878T3 (ar)
PT (1) PT2760878E (ar)
RS (1) RS54521B1 (ar)
SG (1) SG11201400144SA (ar)
SI (1) SI2760878T1 (ar)
TN (1) TN2014000131A1 (ar)
TW (1) TWI537284B (ar)
UA (1) UA107550C2 (ar)
UY (1) UY34356A (ar)
WO (1) WO2013045407A1 (ar)
ZA (1) ZA201401568B (ar)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9512169B2 (en) 2012-07-10 2016-12-06 Bayer Pharma Aktiengesellschaft 3-substituted estra-1,3,5(10),16-tetraene derivatives, methods for the production thereof, pharmaceutical preparations containing same, and use thereof for the production of medicaments
CA2901632C (en) * 2013-02-21 2017-11-07 Bayer Pharma Aktiengesellschaft Estra-1,3,5(10),16-tetraene-3-carboxamides for inhibition of 17.beta.-hydroxysteroid dehydrogenase (akr1 c3)
ES2696848T3 (es) * 2014-09-11 2019-01-18 Bayer Pharma AG Inhibidores de oestra-1,3,5(10),16-tetraeno AKR1C3 sustituido con 3-nitrógeno o azufre
US10167293B2 (en) 2016-05-26 2019-01-01 Bayer Pharma Aktiengesellschaft [8-(phenylsulfonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl](1H-1,2,3-triazol-4-yl)methanones
CZ307437B6 (cs) 2016-06-07 2018-08-22 Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v.v.i. 15β-substituované deriváty estronu jako selektivní inhibitory 17β-hydroxysteoiddehydrogenáz
EP3269373A1 (en) 2016-07-11 2018-01-17 Bayer Pharma Aktiengesellschaft Low-dosed oral dosage form of an akr1c3 inhibitor for treatment of diseases
TW201825478A (zh) 2016-12-19 2018-07-16 德商拜耳製藥公司 ［４－（苯基磺醯基）哌嗪－１－-基］（１ｈ－１，２，３－三唑－４-基）甲酮
EP3555101A2 (en) 2016-12-19 2019-10-23 Bayer Pharma Aktiengesellschaft [(phenylsulfonyl)octahydro-epiminoisoindol-yl](1h-1,2,3-triazol-5-yl)methanones
CA3047191A1 (en) 2016-12-19 2018-06-28 Bayer Pharma Aktiengesellschaft [4-(phenylsulfonyl)piperazin-1-yl](1h-1,2,3-triazol-4-yl)methanones
EP3421483A1 (en) 2017-06-29 2019-01-02 Bayer Pharma Aktiengesellschaft Novel steroidal 17-beta heteroaryl compounds as inhibitors of akr1c3
CN108503695B (zh) * 2018-03-09 2021-06-08 南方医科大学南方医院 基于GnRH多肽衍生物的示踪剂及其制备方法和应用
CN110693892A (zh) * 2018-07-09 2020-01-17 深圳艾欣达伟医药科技有限公司 化合物用于制备预防、治疗或改善疼痛的药物的用途
JP7644713B2 (ja) 2019-03-06 2025-03-12 プロペラ セラピューティクス インコーポレイテッド アビラテロンプロドラッグ
CN113683648B (zh) * 2021-08-26 2025-03-07 上海皓鸿生物医药科技有限公司 一种2’-氟-2’-脱氧尿苷的合成方法及其中间体

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4632003A (en) 1985-07-15 1986-12-30 Kopp William L Musical instrument sound quality enhancement device
US5604213A (en) 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
GB2265624B (en) * 1992-03-31 1995-04-19 British Tech Group 17-substituted steroids useful in cancer treatment
RU2000125533A (ru) * 1998-03-11 2002-10-20 Эндорешерш, Инк. (Ca) Ингибиторы 17-бета-гидроксистероиддегидрогеназ 5 и 3 типа и способы их применения
EP1756139A4 (en) 2004-03-12 2009-07-29 Entremed Inc ANTI-ANGIOGENIC AGENTS
CA2671075A1 (en) * 2006-11-30 2008-06-05 Solvay Pharmaceuticals Gmbh Substituted estratrien derivatives as 17beta hsd inhibitors
GB2470700B (en) 2008-03-25 2012-08-08 Univ Maryland C-17 heteroaryl steroidal CYP17 inhibitors
WO2010091306A1 (en) 2009-02-05 2010-08-12 Tokai Pharmaceuticals Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
BR112012027393B1 (pt) 2010-04-27 2020-12-29 Pharma Mar, S.A uso de um composto lactona esteroidal e composição farmacêutica compreendendo o referido composto

Also Published As

Publication number Publication date
ECSP14013275A (es) 2014-04-30
DOP2014000059A (es) 2014-06-15
AU2012314627B2 (en) 2016-08-18
EP2760878B1 (de) 2015-10-28
UY34356A (es) 2013-04-30
NZ622081A (en) 2015-10-30
PT2760878E (pt) 2016-02-26
WO2013045407A1 (de) 2013-04-04
MA35455B1 (fr) 2014-09-01
CL2014000775A1 (es) 2014-08-18
ZA201401568B (en) 2016-11-30
UA107550C2 (uk) 2015-01-12
KR20140069013A (ko) 2014-06-09
PE20141554A1 (es) 2014-10-24
PL2760878T3 (pl) 2016-04-29
JP5791810B2 (ja) 2015-10-07
GT201400059A (es) 2015-02-17
HUE026645T2 (en) 2016-07-28
TW201317253A (zh) 2013-05-01
CA2850047A1 (en) 2013-04-04
AP2014007598A0 (en) 2014-04-30
DK2760878T3 (en) 2016-01-25
CO6920294A2 (es) 2014-04-10
TWI537284B (zh) 2016-06-11
SI2760878T1 (sl) 2016-02-29
MY175804A (en) 2020-07-09
DE102011083725A1 (de) 2013-04-04
EA025518B1 (ru) 2016-12-30
PH12014500674A1 (en) 2021-08-09
HK1197414A1 (zh) 2015-01-16
CR20140144A (es) 2014-05-16
ES2560257T3 (es) 2016-02-18
AU2012314627A1 (en) 2014-04-10
IL231755A (en) 2016-06-30
MX2014003823A (es) 2014-06-04
EP2760878A1 (de) 2014-08-06
SG11201400144SA (en) 2014-05-29
CN103827133A (zh) 2014-05-28
CN103827133B (zh) 2015-11-25
AR088180A1 (es) 2014-05-14
RS54521B1 (sr) 2016-06-30
EA025518B9 (ru) 2017-10-31
TN2014000131A1 (en) 2015-07-01
US20140249119A1 (en) 2014-09-04
CA2850047C (en) 2016-03-29
HRP20160050T1 (hr) 2016-02-12
CY1117123T1 (el) 2017-04-05
JP2014527994A (ja) 2014-10-23
US9487554B2 (en) 2016-11-08
CU20140037A7 (es) 2014-07-30
EA201490653A1 (ru) 2014-09-30
BR112014007223A2 (pt) 2017-04-04

Similar Documents

Publication Publication Date Title
UA107550C2 (uk) Похідні естра-1,3,5(10),16-тетраєн-3-карбоксаміду, способи їх одержання, фармацевтичні препарати, що їх містять, та їх застосування для виготовлення лікарських засобів
PH12015500274B1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
CY1120429T1 (el) Παραγωγα κιναζολινης για τη θεραπευτικη αντιμετωπιση ιογενων λοιμωξεων και αλλων νοσων
PH12015500713A1 (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
MX373042B (es) Moleculas para administracion a celulas cancerosas mutantes ros1.
MX2014009757A (es) Derivados de isoindolina, composiciones farmaceuticas que los contienen y su uso en terapia.
TN2015000278A1 (en) Autotaxin inhibitors
BR112015011036A2 (pt) derivados de 2-amino-quinazolina substituídos heterocíclicos para o tratamento de infecções virais
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
EA201500112A1 (ru) 3-замещенные производные эстра-1,3,5(10),16-тетраена, способы их получения, фармацевтические средства, которые их содержат, и их использование для получения лекарственных средств
EA201591371A1 (ru) Пиридиновые производные в качестве легкоразлагаемых ингибиторов rock
MX2013003635A (es) Compuestos de n-heteroarilo.
BR112015018071A2 (pt) estra-1,3,5(10),16-tetraeno-3-carboxamidas
MX2016004934A (es) Derivados de aminotetralina y aminoindano, composiciones farmaceuticas que los contienen, y su uso en terapia.
BR112015028890A2 (pt) derivados de piridona para o tratamento de infecções virais e outras doenças
PL402030A1 (pl) Nowe pochodne tiosemikarbazonów, ich kompozycje farmaceutyczne oraz ich zastosowanie